Alkem Labs revises Q3FY26 earnings call to Feb 13, 5 PM IST
Alkem Laboratories Ltd. has rescheduled its Q3FY26 and 9MFY26 earnings conference call to Friday, February 13, 2026, at 5:00 PM IST. The results will be announced on the same day. Dr. Vikas Gupta (CEO) and Mr. Nitin Agrawal (CFO) will represent the company.
This is a procedural update regarding the timing of a conference call, which is a routine corporate event. It does not introduce any new material information about the company's performance or strategic direction, hence the impact is considered low.
The announcement is a routine update regarding a change in the timing of a previously scheduled conference call. It does not contain any new financial information or significant business developments that would indicate a positive or negative sentiment.
Alkem Laboratories Limited has issued a revised intimation regarding its conference call to discuss the financial results for the third quarter (Q3FY26) and the first nine months (9MFY26) of the fiscal year.
The conference call, originally scheduled for Friday, February 13, 2026, at 4:00 PM IST, has been rescheduled to the same day but at 5:00 PM IST. The call will commence at 5:00 PM IST and conclude by 6:00 PM IST.
The company will announce its Q3FY26 and 9MFY26 financial results on Friday, February 13, 2026, prior to the conference call. Representing Alkem Laboratories Limited on the call will be Dr. Vikas Gupta, CEO, and Mr. Nitin Agrawal, CFO. The call will be hosted by Motilal Oswal Securities Ltd.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.